AXIM Biotechnologies (OTCQB: AXIM) has signed a Binding Term Sheet to acquire Dry Eye Disease (DED) testing technology from Advanced Tear Diagnostics, including two FDA-approved ophthalmic diagnostic tests. The acquisition is expected to close by October 1, 2021, with a commercial launch planned for early 2022. DED affects around 20 million people in the U.S., leading to significant impairment in quality of life. The tests are designed for point-of-care usage, providing a quantitative measure for DED diagnosis and potentially tapping into a $9.8 billion market by 2030.
AXIM Biotechnologies (OTCQB: AXIM) announced the completion of pre-clinical drug studies on SPX-1009, a compound targeting malignant melanoma suppression. Conducted by Dr. Douglas Lake at Arizona State University, the study demonstrated promising results in inhibiting the growth of melanoma cells. AXIM plans to initiate animal studies to further assess SPX-1009’s efficacy. There are ongoing patent applications related to this technology. Melanoma cases are projected at 207,390 in 2021 in the U.S., highlighting the potential market for effective treatments.
AXIM Biotechnologies, Inc. (OTCQB: AXIM) announced that its manufacturing partner, Empowered Diagnostics, has applied for emergency approval of ImmunoPass™, a rapid test for measuring COVID-19 neutralizing antibodies. The application is under review by Health Canada, and a CE mark application has also been filed for the EU. Previously, Empowered Diagnostics sought Emergency Use Authorization from the U.S. FDA. CEO John W. Huemoeller II emphasized the importance of rapid testing in managing the pandemic and achieving a return to normalcy.
AXIM Biotechnologies has announced the development of a new ELISA test to measure neutralizing antibodies against six SARS-CoV-2 variants, including those from Brazil and South Africa. This test, which provides results in under two hours, may help evaluate vaccine efficacy against these variants. The company has sought patent protection for this diagnostic innovation. CEO John W. Huemoeller II emphasized the potential benefits for vaccine manufacturers by offering insights into antibody responses. AXIM aims to transform diagnostic procedures in both oncology and COVID-19.
AXIM Biotechnologies has completed successful point-of-care clinical trials for its ImmunoPass rapid test, which measures COVID-19 neutralizing antibodies. Conducted in collaboration with Empowered Diagnostics and a university medical center, the trials confirmed ease of use and accuracy in determining immunity levels. The Company plans to file an Emergency Use Application with the FDA for the test's approval. AXIM is also finalizing additional studies to further validate ImmunoPass’s accuracy under varying conditions.
AXIM Biotechnologies, Inc. has announced the initiation of clinical trials for its rapid point-of-care test, ImmunoPass, designed to measure neutralizing antibodies to COVID-19. As vaccinations progress, monitoring immunity has become crucial to assess vaccine efficacy and timing for booster shots. Unlike existing tests, ImmunoPass focuses on functional neutralizing antibodies, potentially serving as a low-cost alternative for large-scale monitoring. The company's efforts solidify its position in the COVID-19 diagnostic landscape, though market success depends on regulatory approval and demand dynamics.
AXIM® Biotechnologies has filed a provisional patent for a recombinant virus binding protein (VBP) targeting SARS-CoV-2, the virus behind COVID-19. The novel VBP demonstrated to be about 10 times more potent and stable than existing options, potentially lowering research costs for COVID-19 diagnostics. By manufacturing this protein in-house, AXIM aims to eliminate supply chain issues and enhance its research capabilities, including the development of rapid neutralizing antibody tests and specialized face masks. This innovation positions AXIM favorably in the competitive healthcare market.
SAN DIEGO, Sept. 29, 2020 - AXIM Biotechnologies (OTCQB: AXIM) has filed a provisional patent for a revolutionary face mask designed to capture and deactivate SARS-CoV-2, the virus causing COVID-19. The global face mask market, valued at $4.58 billion in 2020, is projected to grow to $21.2 billion by 2026. AXIM's mask utilizes embedded reagents for enhanced virus capture efficiency, surpassing conventional masks. The company is pursuing FDA and EPA approvals and plans to license manufacturers for large-scale distribution.